Abstract
Glucagonomas are relatively rare, and can be difficult to differentiate from other pancreatic tumors. A 62-year-old woman who had suffered from diabetes mellitus was hospitalized for further evaluation of a space-occupying lesion in the head of the pancreas and tumors in the liver. F-18 fluorodeoxyglucose positron emission tomography revealed accumulation of isotope corresponding to a tumor of the pancreas with a standardized uptake value of 4.3, and tumors in the liver with standardized uptake values of 2.4 and 2.8. The serum glucagon level was high (1,170 pg/ml) and the secretin tolerance test was negative. She was diagnosed with glucagonoma with a high serum glucagon level and clinical findings. It is suggested that glucagonoma may be one of the tumors which show high uptake of F-18 fluorodeoxyglucose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boden G. Glucagonoma and insulinomas.Gastroenterol Clin Nor Am 1989; 18: 831–845.
Bergström M, Eriksson B, Öberg K, Sundin A, Ahlström H, Johan K, et al.In vivo demonstration of enzyme activity in endocrine panceatic tumors: Decarboxylation of carbon-11-DOPA to carbon-11-dopamine.J Nucl Med 1996; 37: 32–37.
Alström H, Eriksson B, Bergström M, Bjurling P, Långström B, Öberg K. Pancreatic neuroendocrine tumors: Diagnosis with PET.Radiology 1995; 195: 333–337.
Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32: 623–648.
Yasuda S, Shohtsu A, Tomioka K. F-18 fluorodeoxyglucose positron emission tomography imaging in ectopic non-functioning glucagonoma.Clin Nucl Med 1998; 23: 474–478.
Femández-Represa JA, Rodríguez DF, Contin MJP, Peña ML, Martinez-Sarmiento J, Carreras JL, et al. Pancreatic glucagonoma: Detection by positron emission tomography.Eur J Surg 2000; 166: 175–176.
Lo CY, van Heerden A, Thompson GB, Grant CS, Soreide JA, Harmsen WS. Islet cell carcinoma of the pancreas.World J Surg 1996; 20: 878–884.
McGavran MH, Unger RH, Recant L, Polik HC, Kilo C, Levin ME. A glucagonoma-secreting alpha-cell carcinoma of the pancreas.New Engl J Med 1966; 274: 1408–1413.
Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome.Lancet 1974; ii: 1–5.
Zimny M, Bares R, Faß J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases.Eur J Nucl Med 1997; 24: 678–682.
Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, Delong DM, et al. Diagnosis of pancreatic carcinoma: Role of FDG PET.AJR 1998; 171: 1565–1570.
Bares R, Klever P, Hauptmann S, Helling D, Fass J, Cremerius U, et al. F-18 fluorodeoxyglucose PETin vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.Radiology 1994; 192: 79–86.
Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18 FDG-PET to monitor hepatocellular carcinoma after interventional therapy.J Nucl Med 1994; 35: 1965–1969.
Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine-18 fluorodeoxyglucose in the diagnosis of liver tumors.Ann Nucl Med 2000; 14: 121–126.
Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, et al. Contribution of PET in the detection of liver metastases from pancreatic tumors.Clin Radiol 1999; 54: 248–252.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishiguchi, S., Shiomi, S., Ishizu, H. et al. A case of glucagonoma with high uptake on F-18 fluorodeoxyglucose positron emission tomography. Ann Nucl Med 15, 259–262 (2001). https://doi.org/10.1007/BF02987842
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02987842